| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
SCH-79797 targets the protease-activated receptor 1 (PAR1). PAR1 is a G-protein coupled receptor that is activated by thrombin and plays a key role in platelet aggregation, inflammation, and other processes. SCH-79797 is a selective, non-peptide antagonist that binds to PAR1 and inhibits its activation. It inhibits haTRAP-induced human platelet aggregation, confirming its activity at this receptor.
|
|---|---|
| ln Vitro |
SCH79797 competitively prevents the high-affinity binding of the thrombin receptor activating peptide ([3H]haTRAP). Alpha-thrombin and haTRAP-induced human platelet aggregation is inhibited by SCH79797, but not that of tethering ligand agonists of protease-activated receptor 4 (PAR-4), gamma-thrombin, ADP, or collagen. In hCASMCs, thrombin produces a brief rise in the concentration of cytosolic free Ca2+ ([Ca2+]i). The rise in [Ca2+]i is effectively inhibited by SCH79797. TK-stimulated [3H]thymidine incorporation is totally inhibited by SCH79797 [1] and thrombin. In a concentration-dependent way, SCH79797 impedes the development of several human and animal cell lines. For NIH 3T3, HEK 293, and A375 cells, the corresponding ED50 values for growth inhibition were 75 nM, 81 nM, and 116 nM. At low doses, SCH79797 suppresses serum-stimulated p44/p42 mitogen-activated protein kinase (MAPK) activation in NIH 3T3 cells, but at higher concentrations, it promotes apoptosis [2].
SCH-79797 is a potent PAR1 antagonist with an IC50 of 70 nM and a Ki of 35 nM for inhibiting the binding of a high-affinity thrombin receptor-activating peptide to PAR1. It blocks haTRAP-induced human platelet aggregation. This demonstrates its potent and selective in vitro activity against PAR1. |
| ln Vivo |
In two models of myocardial ischemia/reperfusion (I/R) injury, intact rats' myocardial necrosis following cardiac I/R was decreased by SCH79797 (2.5-250 μg/kg; i.v.; male Sprague Dawley rats) when administered before to or during ischemia. The best dose for the dose-dependent response is 25 μg/kg [4].
While specific in vivo data is not provided, SCH-79797's antagonism of PAR1 suggests it would have activity in animal models of thrombosis, inflammation, and other PAR1-mediated conditions. It is a research tool for studying PAR1 function, implying it has been used in various in vivo studies to elucidate the role of PAR1. |
| Enzyme Assay |
The in vitro activity of SCH-79797 is assessed using radioligand binding assays. The compound is tested for its ability to displace a labeled high-affinity thrombin receptor-activating peptide from PAR1. The IC50 of 70 nM and Ki of 35 nM are determined from these assays.
|
| Cell Assay |
The functional antagonism of SCH-79797 is assessed in cell-based assays. For example, its ability to block haTRAP-induced platelet aggregation is a key functional assay. It can also be tested for its ability to inhibit PAR1-mediated calcium mobilization or other signaling events in cells expressing the receptor.
|
| Animal Protocol |
Animal/Disease Models: Male Sprague Dawley rats (8 weeks old) with myocardial I/R injury [4]
Doses: 2.5 μg/kg, 10 μg/kg, 25 μg/kg, 50 μg/kg, 100 μg/kg and 250 μg/kg Route of Administration: IV Experimental Results: Myocardial necrosis after I/R was diminished in intact rat hearts before or during ischemia. While specific in vivo protocols are not detailed, SCH-79797 is a research tool for studying PAR1. It has likely been used in various animal models to study the role of PAR1 in disease. These studies would involve administering the compound to animals and assessing its effects on relevant physiological or pathological endpoints. |
| ADME/Pharmacokinetics |
SCH-79797 has a molecular weight of 371.48 and a molecular formula of C23H25N5. It is a highly potent, selective nonpeptide PAR1 antagonist. It inhibits PAR1 with an IC50 of 70 nM and a Ki of 35 nM. It is soluble in DMSO and should be stored desiccated at -20°C.
|
| Toxicity/Toxicokinetics |
SCH-79797 is a research compound, and its toxicity profile is not detailed in the provided sources. As a potent antagonist of PAR1, which plays a role in hemostasis, there is a potential for bleeding risk. However, its selectivity suggests it may have a more favorable safety profile than non-selective antagonists.
|
| References |
|
| Additional Infomation |
N3-Cyclopropyl-7-[(4-propyl-2-ylphenyl)methyl]pyrrolo[3,2-f]quinazoline-1,3-diamine is a member of the quinazoline class of compounds.
SCH-79797 (CAS#: 245520-69-8) is a highly potent, selective nonpeptide PAR1 antagonist with an IC50 of 70 nM and a Ki of 35 nM. It inhibits haTRAP-induced human platelet aggregation. SCH-79797 is a valuable research tool for studying PAR1 signaling in thrombosis, inflammation, and other processes. |
| Molecular Formula |
C23H25N5
|
|---|---|
| Molecular Weight |
371.488
|
| Exact Mass |
443.164
|
| CAS # |
245520-69-8
|
| Related CAS # |
SCH79797 dihydrochloride;1216720-69-2
|
| PubChem CID |
4259181
|
| Appearance |
Light yellow to brown solid powder
|
| Boiling Point |
678.3ºC at 760mmHg
|
| Flash Point |
364ºC
|
| Vapour Pressure |
1.23E-18mmHg at 25°C
|
| LogP |
7.17
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)C1=CC=C(C=C1)CN2C=CC3=C2C=CC4=C3C(=NC(=N4)NC5CC5)N
|
| InChi Key |
AVXQPEKZIGPIJW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25N5/c1-14(2)16-5-3-15(4-6-16)13-28-12-11-18-20(28)10-9-19-21(18)22(24)27-23(26-19)25-17-7-8-17/h3-6,9-12,14,17H,7-8,13H2,1-2H3,(H3,24,25,26,27)
|
| Chemical Name |
N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine
|
| Synonyms |
SCH-79797 SCH 79797 SCH79797
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~134.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6919 mL | 13.4593 mL | 26.9186 mL | |
| 5 mM | 0.5384 mL | 2.6919 mL | 5.3837 mL | |
| 10 mM | 0.2692 mL | 1.3459 mL | 2.6919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA